ANIP General Counsel Cook Meredith Sells $37K of Stock

Meredith Cook, Senior Vice President and General Counsel at ANI Pharmaceuticals, Inc. (NasdaqGM: ANIP), sold 500 shares on October 13, 2026, for roughly $36,795. The shares were sold at a price of $73.59 each, which is lower than the previous day's close of $76.14. This transaction was part of a planned selling strategy.

Inside Cook's Trade

Cook's recent sale follows another planned transaction earlier this year in June, where she sold 500 shares for approximately $41,015 at a higher price of $82.03. The timing of her sales contrasts with a general trend of insider transactions at ANI Pharmaceuticals, as other executives, including Stephen Carey, have also sold shares in recent months.

Other Institutional Activity in ANI Pharmaceuticals

In related institutional activity, Blackrock Inc. increased its position by 211,273 shares, reaching a total of 2,958,646 shares valued at about $212.1 million. Soleus Capital Management, L.P. also added 47,493 shares, bringing its total to 867,760 shares valued at roughly $62.2 million. State Street Corporation grew its holdings by 60,032 shares, now owning 831,647 shares worth about $59.6 million. Both Vanguard Capital Management LLC and Tang Capital Management, LLC maintained their positions.

ANI Pharmaceuticals, Inc. Stock Down 0.9%

ANI Pharmaceuticals shares recently traded at $71.63, below their 52-week high of $97.00 and near their low of $69.58. The stock is currently below its 50-day moving average of $76.33, suggesting it has lost some momentum in recent weeks. This context underscores the importance of insider sales as potential indicators of sentiment within the company.

Recent Earnings

In its latest earnings report, ANI Pharmaceuticals generated approximately $978.4 million in revenue, reflecting a growth rate of 25.9%. The company reported an earnings per share (EPS) of $4.59, supported by a net margin of 11.07%. Their next earnings announcement is scheduled for November 6, 2026.

Insider Buying and Selling at ANI Pharmaceuticals, Inc.

Besides Cook’s recent sale, Stephen Carey, the CFO, sold 2,850 shares on September 29, 2026, for about $208,050 at a price of $73.00. Earlier, on June 29, 2026, he sold 2,850 shares at a price of $84.12, totaling around $239,742. These consistent transactions indicate ongoing management adjustments within the company.

Analysts Set New Price Targets

On September 23, 2026, Oppenheimer initiated coverage on ANI Pharmaceuticals with a 'Perform' rating and a price target of $85.00. Guggenheim maintained a 'Buy' rating with a revised target of $119.00 on August 10, 2026, down from $124.00. Canaccord Genuity has a 'Hold' rating with a target of $90.00, indicating mixed opinions on the stock's potential.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc. is a biopharmaceutical firm based in Baudette, Minnesota. It develops and markets both branded and generic pharmaceutical products in the U.S. and internationally. The company's portfolio includes injectables, softgel capsules, and various other dosage forms. With a growing revenue stream and a strong pipeline, it remains an active player in the healthcare sector.

Bottom Line

Meredith Cook's recent sale is part of a broader trend of insider trading at ANI Pharmaceuticals. Investors should monitor the company's upcoming earnings report on November 6, 2026, for insights into its financial health. Remember that this sale reflects past holdings as per the latest disclosures and may not represent current valuations.